Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature

Chrystel Isca 1, Federico Piacentini 1, Ilenia Mastrolia 2, Valentina Masciale 2, Federica Caggia 1, Angela Toss 1, Claudia Piombino 2, Luca Moscetti 3, Monica Barbolini 1, Michela Maur 3, Massimo Dominici 1,2 and Claudia Omarini 3,*

Simple Summary: Breast cancer is a leading cause of female cancer-related death worldwide. Anti-HER2-targeted therapies dramatically improved prognosis for HER2-positive breast cancer patients. Despite that, growing drug resistance due to the pressure of therapy is relatively frequent. For that reason, it is necessary to find biomarkers able to predict treatment sensitivity and survival outcomes. Increasing research has shown how miRNAs, secreted by tumor cells, are strongly involved in cancer development. In this review, we will discuss the recent evidence on the predictive and prognostic value of miRNAs involved in HER2-positive early breast cancer progression.

Abstract: MicroRNAs (miRNA) are small noncoding RNAs that can act as both oncogene and tumor suppressors. Deregulated miRNA expression has been detected in human cancers, including breast cancer (BC). Considering their important roles in tumorigenesis, miRNAs have been investigated as potential prognostic and diagnostic biomarkers. Neoadjuvant setting is an optimal model to investigate in vivo the mechanism of treatment resistance. In the management of human epidermal growth factor receptor-2 (HER2)-positive early BC, the anti-HER2-targeted therapies have drastically changed the survival outcomes. Despite this, growing drug resistance due to the pressure of therapy is relatively frequent. In the present review, we focused on the main miRNAs involved in HER2-positive BC tumorigenesis and discussed the recent evidence on their predictive and prognostic value.

Keywords: exosome; miRNA; extracellular vesicles; HER2 positive breast cancer; early stage breast cancer; neoadjuvant chemotherapy; trastuzumab; predictive factors; prognostic factors

1. Introduction

Breast cancer (BC) is the most common type of cancer diagnosed in women worldwide, with around 2.3 million new cases in 2020 and 685,000 deaths globally according to the World Health Organization [1]. The human epidermal growth factor receptor-2 (HER2) is overexpressed in almost 20% of cases and is generally associated with poorer survival outcomes [2]. Thanks to the advent of anti-HER2-targeted therapies, prognosis for HER2-positive BC patients has dramatically improved [3–12]. Despite their objective activity, intrinsic and acquired resistance to anti-HER2 agents remains a major clinical challenge [13]. To address this problem of resistance, considerable efforts have been made to investigate...
the mechanism of treatment failure. The neoadjuvant setting is an optimal model for studying in vivo the mechanism of treatment resistance [14,15].

Growing evidence has indicated that microRNA (miRNA) profiling could be a promising biomarker for early diagnosis, treatment sensitivity/resistance, and prognosis in different cancer types, including BC [16–18]. MiRNAs are a class of small noncoding regulatory RNAs that are involved in both physiological and pathological processes, such as cancer proliferation [19]. miRNAs can be easily detected in blood and tumor tissue [19]. In particular, miRNAs secreted by cancer cells are packed into extracellular vesicles (EVs) and released into peripheral blood. EVs are largely involved in the cross-talk between cancer cells and the microenvironment [20,21]. The important involvement of EVs and miRNA in ontogenetic processes and their availability in biological fluids, make these molecules optimal biomarkers in oncology [20,22].

This review summarizes the main miRNAs involved in HER2-positive BC tumorigenesis, focusing on their prognostic and predictive role.

2. Extracellular Vesicles and MicroRNAs

EVs are small lipid bilayer-delimited particles that are naturally released by cells and involved in cell communication [23]. EVs can be detected in biological fluids such as serum, plasma, urine, saliva, breast milk, bile, amniotic fluid, and cerebrospinal fluid [24,25]. Once released into the extracellular fluid, EVs may link to the cell plasma membrane, fusing directly with the membrane or being endocytosed, resulting in delivery of proteins and RNA into the target cell [24]. EVs are involved in several biological processes such as antigen presentation, immune regulation, apoptosis evasion, drug resistance, and angiogenesis [25–28]. Based on their size, they are classified into apoptotic bodies (50–5000 nm) released by apoptotic cells, shedding microvesicles/ectosomes (100–1000 nm) produced by budding from the plasma membrane, and exosomes (30–150 nm) that originate from intracellular multivesicular bodies and are secreted in the extracellular space upon fusion with the plasma membrane [20,23,29]. They carry proteins, metabolites, lipids, mRNA, miRNA, long-non-coding RNA, and DNA [24–26,30,31]. A large body of evidence suggests that cancer cells release a higher amount of EVs compared to non-malignant cells [25,26]. The most common methods reported for isolating exosomes from serum or plasma are commercial kits available for the isolation of EVs the size of exosomes (e.g., Total Exosomes Isolation Kit—Invitrogen) [29]. Exosomes contain miRNAs that are strongly involved in the cross-talk between cancer cells and the microenvironment. miRNAs are short, non-coding, single-stranded RNAs of 21–25 nucleotides, which regulate gene expression at a post-transcriptional level by binding to the 3′untranslated region (3′UTR) of its target messenger RNA [32]. miRNAs can be present in the peripheral blood or packed into EVs such as exosomes [29]. MiRNAs are a class of small, noncoding, regulatory RNAs that are involved in both physiological and pathological processes, such as cancer proliferation. In physiological processes, miRNA are produced by non-cancerous cells. The most common techniques reported for miRNA profiling are: microarray analysis; bead-based flow-cytometric techniques; and real-time PCR, SAGE, or RAKE assay, with peculiar strengths and weaknesses under investigation [33–37].

3. miRNAs in HER2-Positive Breast Cancer

Several preclinical and clinical studies have focused their attention on the research of miRNAs linked to HER2 pathways in BC. In most of these cases, miRNAs were isolated from tumor tissues (cell lines or formalin-fixed paraffin embedded samples). Table 1 summarizes all the miRNAs known to be involved in HER2-positive BC tumorigenesis. The most widely reported miRNAs in the literature are: miR-155, miR-21, miR-205, and miR-125 families. In the literature, the most widely cited miRNAs related to HER2-positive subtypes are the following:

miR-155 has been found upregulated in HER2-positive BC in both early and metastatic settings [38]. miR-155 has an oncogene function in the interaction with the MAPK pathway.
through constitutive activation of STATs proteins by inhibiting SOCS1 gene and activating AKT and Src [39,40].

miR-21 is one of the most investigated miRNAs in oncology. It has been found overexpressed in all BC subtypes, but mainly in the HER2-positive hormone receptors negative subtype [41,42]. In particular, high expression of miR-21 has been found to significantly correlate with more aggressive tumor behavior (larger tumor with high nuclear grade) and poor survival outcomes [43]. In vitro studies have shown that up-regulation of miR-21 induced by HER2/neu signaling via MAPK (ERK1/2) pathway promotes cell invasion through downregulation of PDCD4 (programmed cell death 4) [43].

miR-205 has been detected in serum of BC patients with a decreasing expression from the less aggressive BC subtypes to the more aggressive ones, mainly in HER2-positive and triple-negative tumors [44,45]. It targets HER3 directly, inhibiting SKBr3 in BC cell lines [46,47]. Its oncosuppressive role is also linked by EMT suppression [45].

Table 1. HER2-positive breast cancer miRNA expression.

| miRNA    | Expression Level | Gene Target | Action                                                                 | Evidence       | Sample      | References |
|----------|------------------|-------------|----------------------------------------------------------------------|----------------|-------------|------------|
| miR-489  | down             | SMAD3, SHP2, HER2 | Cell growth, invasion and EMT inhibition (decreased expression of HER2) | clinical/preclinical tissue | tissue      | [48]       |
| miR-520kd| down             | TWIST1      | Restoration of E-cadherine expression (reduction in invasiveness)     | clinical/preclinical tissue | tissue      | [49,50]    |
| miR-376b | up               | Hoxd10      | Angiogenesis                                                          | clinical/preclinical tissue | tissue      | [51,52]    |
| miR-342-5p| down            | ERK, MAPK, SAPK/JNK | HER2 downstream inhibiting effect                                      | preclinical tissue | tissue      | [53]       |
| miR-375  | up/down          | PAX6, IGF1R | Tumor suppressor (HER2, HR + -negative and inflammatory BC §-related) | preclinical tissue | tissue/blood | [54–56]    |
| miR-155  | up               | SOCS1, JAK2/STAT3, FOXO3 | HER2-positive status and TNBC correlation (cell proliferation) | clinical/preclinical tissue | tissue      | [38,39]    |
| miR-181c | down             | OPN         | Increased HER2-positive signature, enhanced chemosensitivity         | clinical/preclinical tissue | tissue      | [51,57,58] |
| miR-302c | up               | MEKK1       | Increased HER2-positive signature, enhanced chemosensitivity         | clinical/preclinical tissue | tissue      | [51,59]    |
| miR-30e-3p| up/down          | CTHRC1     | Increased HER2-positive signature, proliferation inhibition, and apoptosis HER2-positive and HR * negative status association | clinical/preclinical tissue | tissue      | [51,60]    |
| miR-200  | up/down          | EGFR, SIRT1 | Tumor suppressor (cell cycle arrest and apoptosis)                   | clinical/preclinical tissue | tissue/blood | [45,63,64] |
| miR-205  | down             | EGFR, VEGF-A, HER3, ZEB1, SIP1, E2F | Tumor suppressor (cell cycle arrest and apoptosis)                   | clinical/preclinical tissue/blood | tissue/blood | [61,62]    |
| miR-122-5p| up               | ADAM10      | Tumor suppressor (cell cycle arrest and apoptosis)                   | preclinical clinical tissue | tissue      | [65]       |
| miR-125b | up               | ERBB2,BAK1, BCL-2, STARD13 | Increased migration and invasion                                       | clinical/tissue | tissue      | [66]       |
| miR-125a-5p| down            | EGFR family, AKT-ERK PDCD4, PTEN, TPM1, MAPK, EGFR family | Tumor suppressor (invasion reduction)                             | clinical/preclinical tissue | tissue      | [61]       |
| miR-21   | up               | HER2/neu upregulation correlation and apoptosis inhibition     | clinical/preclinical tissue | [41,61]    |
| miR-147  | down             | EGFR1, AKT2, CDK4, RB1 | EGFR-driven cell-cycle (cell proliferation inhibition)         | preclinical tissue | [67]       |
| miR-124  | down             | EGFR1, STAT3 | Cell growth and differentiation inhibition                              | preclinical tissue | [68]       |

# Gene targets included in the table were identified through an in silico analysis; * HR: hormone receptors; § BC: breast cancer.
Its downregulation in serum of BC patients compared to healthy people suggests a possible role as a marker for BC diagnosis [63,64].

miR-125b belongs to the miR-125 family. miR-125b is generated from two genes: miR-125b-1 (on chromosome 11q24) and miR-125b-2 (on chromosome 21q21). It can be up- or downregulated depending on the tumor type [69–72]. In BC patients, its upregulation seems to promote EMT expression with an important implication in metastasis development [73]. Other direct targets of miR-125b are the EGFR family genes, mainly ERBB2 and ERBB3. In particular, in BC cell lines, miR-125b seems to induce a suppression of these genes [74]. Evidence from paraffin-embedded BC tissue samples reported a significant correlation between miR125b expression and HER2 expression (p < 0.001), with an important prognostic implication for the patient’s overall survival (OS) [66].

Finally, Lowery et al, through the expression profiling analysis of 453 miRNAs from formalin-fixed paraffin-embedded samples of 29 early BC patients, using an artificial neural network (ANN) and RQ-PCR for validation, reported a signature of five miRNAs (miR-520d, miR-181c, miR-302c, miR-376b, and miR-30e-3p), which seemed to accurately predict HER2 status in early BC patients [51].

4. Predictive Biomarkers

The identification of biomarkers able to predict treatment sensitivity before any intervention remains one of the main goals for oncologists. Thanks to the easy availability of miRNAs, they can be an optimal biomarker. Several published papers investigated the predictive role of miRNAs isolated in both BC tissue and blood. Table 2 summarizes miRNAs known to be predictive of chemotherapy or anti-HER2-targeted therapy sensitivity. In particular, data from different clinical and preclinical studies identified miR-125b, miR21, miR-210, and miR-155 as predictive biomarkers of trastuzumab resistance. Circulating miR-125b in blood serum of early BC patients seems to be significantly associated with neoadjuvant chemotherapy response. In particular, higher expression levels of miR-125b have been reported in resistant patients compared to responsive ones [75]. Wang et al. demonstrated an association between higher miR-125b expression and a higher percentage of proliferating cells in BC tissue [75]. Biologically, it can be explained by the Bak1 (Bcl-2 antagonist Killer 1) downregulation induced by miR-125b, which suppresses drug efficacy [76]. Bak1 is also known to be involved in the epithelial–mesenchymal transition process through EMT dysregulation, resulting in an increased resistance to chemotherapy [77]. In addition, preclinical evidence has suggested that the upregulation of miR-21 induced trastuzumab resistance due to the reduction of PTEN gene expression [78–80].

Another possible biological mechanism of resistance is PI3K pathway dysregulation by miR-21 and EMT activation with the triggering of IL-6/STAT3/NF-kB-mediated signaling [81]. A study by Liu et al on circulating miR-21 (ser-mir21) in HER2-positive early BC patients treated with neoadjuvant chemotherapy plus trastuzumab showed a significant correlation between changes in ser-miR-21 expression and treatment sensitivity [78]. The authors reported a significant reduction of expression of ser-miR-21 levels at the end of the second cycle and at the end of neoadjuvant treatment compared to the baseline value (before start of treatment), mainly shown in clinical responders (p < 0.001). These results were confirmed by Rodriguez-Martinez et al., who observed lower levels of miR-21 in HER2-positive patients during neoadjuvant treatment with trastuzumab [79]. They also highlighted a significant association between higher levels of exosomal miR-21 and circulating tumor cells [79]. In a study by Jung et al. on plasma samples of BC patients who underwent neoadjuvant trastuzumab-based chemotherapy, levels of miR-210 inversely correlated with treatment response. Higher levels of miR-201 have been reported in patients with residual disease compared to those with pathologically complete response (p = 0.0359) [82]. An in vitro study confirmed these data, showing a higher expression of miR-21 in trastuzumab-resistant BT474 cells [82]. miR-155 was identified as a negative predictive marker too. In a cohort of 175 BC patients, 107 early stage and 68 in the metastatic setting, the upregulation of miR-155 was related to poor trastuzumab sensitivity [83].
Table 2. Predictive value for treatment outcomes of miRNAs expressed in HER2-positive early breast cancer.

| miRNA   | Expression Level | Gene Targets                              | Action                                        | Evidence     | Sample       | References |
|---------|------------------|-------------------------------------------|-----------------------------------------------|--------------|--------------|------------|
| miR-210 | up               | RAD52, FGFR1, E2F3, ephrin A3, MET, IGF1R, MUC4 | Trastuzumab resistance                        | preclinical/ clinical | tissue/blood | [82,84]   |
| miR-375 | down             | IGF1R, JAK2/STAT3                           | Trastuzumab, tamoxifene, and adriamycin resistance | preclinical/ clinical | tissue/blood | [55,56,85] |
| miR-205 | up               | EGFR, VEGF-A, HER3, AKT ERBB2, BAK1, BCL-2, STARID13 | Increased sensitivity to anti-HER2 therapy | preclinical | tissue       | [61]       |
| miR-125 | up               | ERBB2, BAK1, BCL-2, NFKB, MAPK, PTEN STARD13 | Resistance to anthracycline/taxol-based therapies | preclinical/ clinical | tissue/blood | [75]       |
| miR-30c | up               | TWF1, IL-11, YWHAZ                          | Increased sensitivity to taxol, doxorubicin and tamoxifene | preclinical | tissue       | [86,87]   |
| miR-26a | up               | CCNE2                                      | Increased sensitivity to trastuzumab           | preclinical | tissue       | [88]       |
| miR-34a | down             | BCL-2, CCND1, NOTCH1                        | RT sensitivity, multidrug resistance          | preclinical/ clinical | tissue      | [90]       |
| miR-122-5p | up             | ADAM10                                     | Increased sensitivity to trastuzumab           | clinical    | tissue       | [65]       |
| miR-23b-3p | up             | PTEN                                       | Trastuzumab resistance                        | preclinical | tissue       | [91]       |
| miR-195-5p | down           | VEGFA, RAF 1, FGFR2, AKT3, CCND1, MYB      | Trastuzumab resistance                        | preclinical | tissue       | [91]       |
| miR-656-5p | down           | CREB1                                      | Trastuzumab resistance                        | preclinical | tissue       | [91]       |
| miR-340-5p | down           | C-MET                                      | Trastuzumab resistance                        | preclinical | tissue       | [91]       |
| miR-770-5p | up             | PI3K, MAPK                                 | Potentiated trastuzumab effect                | preclinical | tissue       | [92]       |
| miR-200b | up               | PTEN                                       | Trastuzumab resistance                        | preclinical/ clinical | tissue/blood | [93]       |
| miR-135b | up               | CyclinD2                                   | Increased sensitivity to trastuzumab          | preclinical/ clinical | tissue/blood | [93,94]   |
| miR-29a | up               | IGF-1R, PTEN                               | Trastuzumab and adryamicin resistance         | preclinical/ clinical | tissue/blood | [95,96]   |
| miR-141 | down             | ERBB4                                      | Trastuzumab resistance                        | preclinical | tissue       | [97]       |
| miR-148 | up               | MAPK/ERK (ERBB3 genes)                     | Increased pathological complete response       | clinical     | blood        | [98]       |
| miR-155 | up               | SOCS1,STAT3                                | Trastuzumab resistance                        | preclinical/ clinical | tissue/blood | [39,83]   |
| miR-221 | up               | PTEN                                       | Trastuzumab resistance                        | preclinical | tissue       | [99]       |

* Gene targets included in the table were identified through an in silico analysis.

On the contrary, miR-148a-3p and miR-205 seem to be positive predictive biomarkers for anti-HER2-targeted therapies. In particular, the early blood detection of miR-148a-3p seems to identify early responsive patients to neoadjuvant anti-HER2 treatments [100]. Indeed, the study by Di Cosimo et al. demonstrated a strong correlation between miR-148a-3p and a pathologically complete response in a BC population treated with primary trastuzumab \( (p = 0.008) \) [100]. Consistently, in vitro studies reported that miR-148a overexpression inhibits BC cell proliferation through inhibition of the MAPK/ERK signaling pathways by direct targeting of ERBB3 genes and angiogenesis inhibition [98]. Preclinical
evidence has shown how the miR-205 restores a pro-apoptotic activity. In BC tissues, miR-205 directly targets HER3 receptor and inhibits the AKT-mediated survival pathway, increasing the responsiveness to both tyrosine kinase inhibitors (such as Lapatinib and Gefitinib) and trastuzumab [47,101]. Finally, a recent preclinical study showed a significant dysregulation of four miRNAs (miR-23b-3p, miR-195-5p, miR-656-5p, miR-340-5p) in HER2-positive BC-resistant BT-474 cells, suggesting potential involvement of these miRNAs in trastuzumab resistance mechanisms [91].

5. Prognostic Biomarkers

As well as the predictive role of miRNAs being widely investigated, their prognostic value has also been studied (Table 3). The most widely reported miRNAs as negative prognostic biomarkers are: miR-21, miR-155, miR-150-5p, and miR-4734. miR-21 demonstrated an important prognostic role in HER2-positive early BC patients receiving neoadjuvant chemotherapy combined with trastuzumab [78]. In particular, Liu et al. demonstrated a better OS and disease-free survival (DFS) in patients with decreased ser-miR-21 from the start to the end of neoadjuvant treatment [78]. Higher levels seemed to be associated with larger tumor size and high Ki67 expression, with a statistically significant correlation with higher stage ($p = 0.008$) and tumor grade ($p = 0.005$). In particular, HER2-positive BC subtype ($p = 0.002$) and negative estrogen receptor cancer ($p = 0.002$) had a significantly higher expression of miR-21 [41]. Moreover, in a study on serum samples from 127 patients with early HER2-positive BC undergoing neoadjuvant treatment, increased levels of circulating miR-21 before and after chemotherapy showed a significant association with poor OS [84]. In early BC, higher miR-155 expression showed a strong correlation with poor event-free survival too, in univariate and multivariate analyses [83]. Du et al. identified two intracellular miRNAs, miR-150-5p and miR-4734, as reliable prognostic biomarkers predicting development of recurrence disease in HER2-positive BC after adjuvant trastuzumab-based treatment [102].

Contrasting clinical roles have been reported for miR-125. In particular, miR-125-b was identified as a negative prognostic factor, associated with worse OS in HER2-positive BC patients [66]. On the contrary, miR-125a-5p was a positive prognostic factor. A low expression level was found in the serum of patients with shorter survival compared to long-term patients. It also had a negative correlation with tumor grade ($p = 0.004$), lymph-node status ($p = 0.004$), and tumor size ($p < 0.001$). [103].

Both miR-205 and miR-148a seem to be positive prognostic factors. In a clinical study on 52 HER2-positive BC patients treated with adjuvant trastuzumab, miR-205 expression on sample tissues significantly correlated to better DFS ($p = 0.00168$) [101]. In addition, in cell lines, lower levels of miR-205 were correlated to high histological grade biopsies and higher invasion rate [104]. In preclinical evidence, miR-148a inhibits BC cell migration and invasion, through wnt-β-catenin pathway inhibition [105] and MMP-13 downregulation [106], resulting in a pro-apoptotic activity [107]. Among positive prognostic factors, miR-145 has been reported by Quan et al. as downregulated in tumor samples more than in paracancerous tissue [108]. In agreement with its oncosuppressive function, higher miR-145 levels seem to be associated with a better survival rate than the lower expression group ($p < 0.028$) [48,108].

As expected, due to the close connection between predictive and prognostic value, some miRNAs overlap between Tables 1 and 2, specifically, miR-210, miR-205, miR-21, miR-125b, and miR-148. High expression levels of miR-210, miR-21, and miR-125b correlate to trastuzumab and/or chemotherapy resistance and to poor survival, accordingly [66,75,78,107,82,84]. On the contrary, high expression of miR-205 and miR-148 correlated to an increase in sensitivity to cytotoxic treatments and a higher number of pathologically complete responses at the end of the neoadjuvant therapy, with an improvement in OS [104–107].
Table 3. Prognostic value of miRNAs expressed in HER2-positive early breast cancer.

| miRNA     | Expression Level | Pos/Neg | Action                                                                 | Evidence       | Sample          | References |
|-----------|------------------|---------|------------------------------------------------------------------------|----------------|-----------------|------------|
| miR-21    | up               | neg     | Reduction during treatment: better OS and DFS (high level in high histological grade and invasion rate) | preclinical/clinical | tissue/blood    | [41,78,84] |
| miR-122   | up               | neg     | Circulating higher levels associated with metastasis                  | clinical       | tissue/blood    | [54,109]   |
| miR-155   | up               | neg     | High levels predicts poor event free/progression free survival         | clinical       | blood           | [83]       |
| miR-205   | up               | pos     | Low level associated with worse prognosis (high level in high histological grade and invasion rate) | preclinical     | tissue          | [104]      |
| miR-30a   | up               | pos     | Low level associated with higher grade and TNM stage                  | clinical       | tissue          | [110]      |
| miR-210   | up               | neg     | Reduced RFS                                                            | preclinical     | blood           | [84]       |
| miR-125b  | up               | neg     | Worse OS                                                               | clinical       | tissue          | [66]       |
| miR-125a-5p | up       | pos     | Low levels associated with poor survival, high grade, lymph node status, and tumor size | preclinical/clinical | tissue/blood    | [103]      |
| miR-10b   | up               | neg     | Correlation with tumor stage and lymph node positivity                 | preclinical/clinical | tissue          | [111,112]  |
| miR-373   | up               | neg     | Correlation with advanced clinical stage                               | preclinical     | tissue/blood    | [84,113]   |
| miR-148a  | up               | pos     | Migration and invasion cancer cell inhibition (pro-apoptotic function) | preclinical     | tissue          | [105–107]  |
| miR-145   | up               | pos     | Low levels correlate with poor survival outcomes                        | preclinical/clinical | tissue          | [108,114,115] |
| miR-4734  | up               | neg     | Disease recurrence (ERBB2 amplification)                               | preclinical/clinical | tissue          | [102,116]  |
| miR-150-5p| up               | neg     | Disease recurrence (enhanced cell proliferation, invasion, and migration) | preclinical/clinical | tissue          | [102,117]  |
| miR-489   | down             | neg     | Low level correlates with shorter OS                                   | preclinical     | clinical        | [92]       |
| miR-770-5p| up               | pos     | Cell invasion and motility inhibition                                  | preclinical/clinical | tissue          | [118]      |
| miR-342-5p| up               | pos     | Better OS and increased time to progression (cell proliferation inhibition) | preclinical/clinical | tissue          | [53,119]   |

6. Conclusions

Emerging evidence highlights the key role in cell-to-cell communication and tumorigenesis of miRNAs. Due to their easy availability in blood and tumor tissue, they represent the optimal biomarker in oncology. Actually, a great deal of effort has been put into basic and clinical research to isolate a signature of miRNAs with predictive and prognostic value. This issue is particularly important in patients treated with targeted therapies, such as HER2-positive BC therapies. Data from our review identified a panel of miRNAs expressed in HER2-positive BC potentially able to predict treatment and survival outcomes. Unfortunately, available data are not enough to define whether some miRNAs are better predictors than others. In the available studies, the miRNA level changes were evaluated in different ways, using fold change in some cases and p-value in others, which made a comparison between the studies difficult. Moreover, further investigations would be necessary to properly define and validate these molecular tools as clinical biomarkers. Despite this, our literature review identified a triplet of miRNAs (155, 125b, 21), typically expressed in HER2-positive BC, that seem to be valid negative predictive and prognostic biomarkers. Available evidence is promising but requires further data from clinical trials. A future development could be the periodic assessment of a panel of HER2-specific miRNAs in patients on neoadjuvant treatment to enable early prediction of treatment resistance and to tailor patient management.
Author Contributions: C.O., M.D. and F.P., conceptualization. C.I., M.B., A.T. and C.P., writing—original draft preparation and review and editing. E.C., I.M. and V.M., original draft preparation and visualization. C.O., M.M. and L.M., supervision. M.D., project administration. All authors have read and agreed to the published version of the manuscript.

Funding: The authors received no financial support for the research.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

BC breast cancer
HER2 human epidermal growth factor receptor-2
miRNA microRNA
EVs extracellular vesicles
OS overall survival
DFS disease-free survival

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef]

2. Cronin, K.A.; Harlan, L.C.; Dodd, K.W.; Abrams, J.S.; Ballard-Barbash, R. Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US. Cancer Invest. 2010, 28, 963–968. [CrossRef] [PubMed]

3. Swain, S.M.; Miles, D.; Kim, S.-B.; Im, Y.-H.; Im, S.-A.; Semiglazov, V.; Ciruelos, E.; Schneeweiss, A.; Loi, S.; Monturus, E.; et al. Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020, 21, 519–530. [CrossRef]

4. Piccart-Gebhart, M.J.; Procter, M.; Leyland-Jones, B.; Goldhirsch, A.; Untch, M.; Smith, I.; Gianni, L.; Baserga, J.; Bell, R.; Jackisch, C.; et al. Trastuzumab after Adjuvant Chemotherapy in HER2-positive Breast cancer. N. Engl. J. Med. 2005, 353, 1659–1672. [CrossRef] [PubMed]

5. Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E.; Davidson, N.E.; Tan-Chiu, E.; Martin, S.; Paik, S.; Kaufman, P.A.; et al. Trastuzumab plus Adjuvant chemotherapy for Operable HER2-Positive Breast cancer. N. Engl. J. Med. 2005, 353, 1673–1684. [CrossRef] [PubMed]

6. Cameron, D.; Piccart-Gebhart, M.J.; Gelber, R.D.; Procter, M.; Goldhirsch, A.; de Azambuja, E.; Castro Jr, G.; Untch, M.; Smith, I.; Gianni, L.; et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017, 389, 1195–1205. [CrossRef]

7. Perez, E.A.; Romond, E.H.; Suman, V.J.; Jeong, J.-H.; Sledge, G.; Geyer Jr, C.E.; Martin, S.; Rastogi, P.; Gralow, J.; Swain, S.M.; et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J. Clin. Oncol. 2014, 32, 3744–3752. [CrossRef]

8. Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M.; et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N. Engl. J. Med. 2011, 365, 1273–1283. [CrossRef]

9. Von Minckwitz, G.; Huang, C.-S.; Mano, M.S.; Loibl, S.; Mamounas, E.P.; Untch, M.; Wolmark, N.; Rastogi, P.; Schneeweiss, A.; Redondo, A.; et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N. Engl. J. Med. 2019, 380, 617–628. [CrossRef]

10. Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baserga, J.; Pegram, M.; Oh, D.-Y.; Diéras, V.; Guardino, E.; et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N. Engl. J. Med. 2012, 367, 1783–1791. [CrossRef]

11. Krop, I.E.; Kim, S.-B.; González-Martin, A.; LoRusso, P.M.; Ferrero, J.M.; Smith, M.; Yu, R.; Leung, A.C.F.; Wildiers, H. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15, 689–699. [CrossRef]

12. Modi, S.; Saura, C.; Yamashita, T.; Park, Y.H.; Kim, S.-B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsuturani, J.; et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N. Engl. J. Med. 2020, 382, 610–621. [CrossRef] [PubMed]

13. Vernieri, C.; Milano, M.; Brambilla, M.; Mennitto, A.; Maggi, C.; Cona, M.S.; Prisciandaro, M.; Fabbroni, C.; Celio, L.; Mariani, G.; et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Crit. Rev. Oncol. Hematol. 2019, 139, 53–66. [CrossRef] [PubMed]
14. Gianni, L.; Pienkowski, T.; Im, Y.-H.; Roman, L.; Tseng, L.-M.; Liu, M.-C.; Lluch, A.; Staroslawska, E.; de la Haba-Rodriguez, J.; Im, S.-A.; et al. Efficacy and Safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced inflammatory or Early HER2 positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2012, 13, 25–32. [CrossRef]  

15. Schneeberger, A.; Chia, S.; Hickish, T.; Harvey, V.; Eniu, A.; Hegg, R.; Tausch, C.; Seo, J.H.; Tsai, Y.-F.; Ratnayake, J.; et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). *Ann. Oncol.* 2013, 24, 2278–2284. [CrossRef] [PubMed]  

16. Hannafon, B.N.; Trigoso, Y.D.; Calloway, C.L.; Zhao, Y.D.; Lum, D.H.; Welm, A.L.; Zhao, Z.J.; Blick, K.E.; Dooley, W.C.; Ding, W.Q. Plasma exosome microRNAs are indicative of breast cancer. *Breast Cancer Res.* 2016, 18, 1–14. [CrossRef] [PubMed]  

17. Shimomura, A.; Shino, S.; Kawauchi, J.; Takizawa, S.; Sakamoto, H.; Matsuzaki, J.; Ono, M.; Takeshita, F.; Niida, S.; Shimizu, C.; et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. *Cancer Sci.* 2016, 107, 326–333. [CrossRef] [PubMed]  

18. Quan, J.; Liu, S.; Dai, K.; Jin, L.; He, T.; Pan, X.; Lai, Y. Micro-RNA-23a/24–2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta-analysis. *Mol. Clin. Oncol.* 2018, 8, 159–169. [PubMed]  

19. Hannafon, B.N.; Ding, W.-Q. Intercellular communication by exosome-derived microRNAs in cancer. *Int. J. Mol. Sci.* 2013, 14, 14240–14269. [CrossRef]  

20. Piomibboni, C.; Mastrolia, I.; Omarini, C.; Candini, O.; Dominici, M.; Piccini, F.; Toss, A. The role of exosomes in cancer. *Biomedicines* 2021, 9, 312. [CrossRef]  

21. Kalluri, R. The biology and function of exosomes. *J. Clin. Investig.* 2016, 126, 1208–1215. [CrossRef]  

22. Wu, H.; Wang, Q.; Zhong, H.; Li, L.; Zhang, Q.; Huang, Q.; Yu, Z. Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next-generation sequencing. *Oncol. Rep.* 2020, 43, 240–250. [CrossRef]  

23. Kalra, H.; Drummen, G.P.C.; Mathivanan, S. Focus on Extracellular Vesicles: Introducing the Next Small Big Thing. *Clin. Cancer Res.* 2016, 11, 7350–7359. [CrossRef]  

24. Raposo, G.; Stoorvogel, W. Extracellular vesicles: Exosomes, microvesicles, and friends. *J. Cell Biol.* 2013, 200, 373–383. [CrossRef]  

25. Yáñez-Mo´, M.; Siljand, P.-R.-M.; Andreu, Z.; Deauve, A.B.; Borràs, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological functions. *J. Extracell. Vesicles* 2015, 4, 27066. [CrossRef]  

26. Kormelink, T.G.; Mol, S.; de Jong, E.C.; Wauben, M.H.M. The role of extracellular vesicles when innate meets adaptive. *Semin. Immunopathol.* 2018, 40, 439–452. [CrossRef] [PubMed]  

27. Peinado, H.; AléKovi´c, M.; Lavotshkin, S.; Matei, I.; Costa-Silva, B.; Moreno-Bueno, G.; Hergueta-Redondo, M.; Williams, C.; García-Santos, G.; Ghajar, C.; et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. *Nat. Med.* 2012, 18, 883–891. [CrossRef] [PubMed]  

28. Thierry, A.R.; Messaoudi, S.E.I.; Gahan, P.B.; Anker, P.; Stroum, M. Origins, structures, and functions of circulating DNA in oncology. *Cancer Metastasis Rev.* 2016, 35, 374–376. [CrossRef]  

29. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Borràs, F.E.; Bergin, L.; Gorria, A.R.; Pérez-Gálvez, A.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles. *Ann. Oncol.* 2018, 29, 1535750. [CrossRef]  

30. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell* 2004, 116, 281–297. [CrossRef]  

31. Liu, C.G.; Calin, G.A.; Meloon, B.; Gamliel, N.; Sevignani, C.; Ferracin, M.; Dumitru, C.D.; Shimizu, M.; Zupo, S.; Dono, M.; et al. An oligonucleotide microchip for genome wide miRNA profiling in human and mouse tissues. *Proc. Natl. Acad. Sci. USA* 2004, 101, 9740–9744. [CrossRef] [PubMed]  

32. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human cancers. *Nature* 2005, 435, 834–838. [CrossRef] [PubMed]  

33. Chen, C.; Randal, D.A.; Broomer, A.J.; Zhou, Z.; Lee, D.H.; Nguyen, J.T.; Babissun, M.; Xu, N.L.; Mahuvakar, V.R.; Andersen, M.R.; et al. Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic Acids Res.* 2005, 33, e179. [CrossRef] [PubMed]  

34. Cummins, J.M.; He, Y.; Leary, R.J.; Pagliarini, R.; Zhou, Y.; Zhao, D.; Bart, O.; Bentwich, Z.; Szafranska, A.E.; Labourier, E.; et al. The colorectal microRNAome. *Proc. Natl. Acad. Sci. USA* 2006, 103, 3687–3692. [CrossRef] [PubMed]  

35. Nelson, P.T.; Baldwin, D.A.; Scarch, L.M.; Oberholzer, T.; Tobias, J.W.; Murrelalots, Z. Microarray-based, high-throughput gene expression profiling of microRNAs. *Nat. Methods* 2004, 1, 155–161. [CrossRef]  

36. Song, C.G.; Wu, X.Y.; Fu, F.-M.; Han, Z.-H.; Wang, C.; Shao, Z.-M. Correlation of miR-155 on formalin-fixed paraffin embedded tissues with invasiveness and prognosis of breast cancer. *Zhonghua Wai Ke Za Za Zhi* 2012, 50, 1011–1014. [CrossRef]  

37. Jiang, S.; Zhang, H.-W.; Lu, M.-H.; He, X.-H.; Li, Y.; Gu, H.; Liu, M.-F.; Wang, E.-D. MicroRNA-155 functions as an Oncore in breast cancer by targeting the suppressor of cytokine signaling 1 gene. *Cancer Res.* 2010, 70, 3119–3122. [CrossRef]
40. Nami, B.; Wang, Z. HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance. *Cancers* 2017, 9, 40. [CrossRef]
41. Lee, J.A.; Lee, H.Y.; Lee, E.S.; Kim, I.; Bae, J.W. Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. *J. Breast Cancer* 2011, 14, 269–275. [CrossRef]
42. Sempere, L.F.; Christensen, M.; Silahtaroglu, A.; Bak, M.; Heath, C.V.; Schwartz, G.; Wells, W.; Kauppinen, S.; Cole, C.N. Altered MicroRNA Expression Confined to Specific Epithelial Cell Subpopulations in Breast Cancer. *Cancer Res.* 2007, 67, 11612–11620. [CrossRef]
43. Huang, T.-H.; Wu, F.; Loeb, G.B.; Hsu, R.; Heidestersbachi, A.; Brincat, A.; Horiruchi, D.; Lebbink, R.J.; Mo, Y.-Y.; Goga, A.; et al. Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion. *J. Biol. Chem.* 2009, 284, 18515–18524. [CrossRef] [PubMed]
44. Xiao, Y.; Humphries, B.; Yang, C.; Wang, Z. MiR-205 Dysregulations in Breast Cancer: The Complexity and Opportunities. *Non-Coding RNA* 2019, 5, 53. [CrossRef] [PubMed]
45. Plantamura, I.; Cataldo, A.; Cosentino, G.; Iorio, M.V. miR-205 in Breast Cancer: State of the Art. *Int. J. Mol. Sci.* 2021, 22, 27. [CrossRef] [PubMed]
46. Wu, H.; Zhu, S.; Mo, Y.-Y. Suppression of cell growth and invasion by miR-205 in breast cancer. *Cell Res.* 2009, 19, 439–448. [CrossRef] [PubMed]
47. Iorio, M.; Casalini, P.; Piovano, C.; Di Leva, G.; Merlo, A.; Triulzi, T.; Ménard, S.; Croce, C.M.; Tagliaabue, E. microRNA-205 Regulates HER3 in Human Breast Cancer. *Cancer Res.* 2009, 69, 2195–2200. [CrossRef] [PubMed]
48. Patel, Y.; Shah, N.; Lee, J.S.; Markoutsa, E.; Jie, C.; Liu, S.; Bobtyl, R.; Reisman, D.; Xu, P.; Chen, H. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth. *Oncotarget* 2016, 7, 18295–18308. [CrossRef]
49. Savad, S.; Mahdipour, P.; Shirdast, H.; Nekooehes, L.; Nekooehes, L.; Shirkoohi, R.; Nekoohesh, L.; Shirkoohi, R.; Nikooee, V.; Miryounesi, M.; Modarresi, M.H. Expression of miR-520d in breast cancer. *Basic Clin. Cancer Res.* 2013, 5, 11–15.
50. Tashkandi, H.; Shah, N.; Patel, Y.; Chen, H.; Patel, Y.; Chen, H. Identification of new miRNA biomarkers associated with HER2-positive breast carcinomas of the Breast. *Oncoscience* 2013, 2, 79–92. [CrossRef] [PubMed]
51. Lowery, A.J.; Miller, N.; Devaney, A.; McNeill, R.E.; Davoren, P.A.; Lemetre, C.; Benes, V.; Schmidt, S.; Blake, J.; Ball, G.; et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. *Breast Cancer Res.* 2009, 11, R27. [CrossRef] [PubMed]
52. An, N.; Luo, X.; Zhang, M.; Yu, R. MicroRNA-376b promotes breast cancer metastasis by targeting Hoxd10 directly. *Exp. Ther. Med.* 2017, 13, 79–84. [CrossRef] [PubMed]
53. Lindholm, E.M.; Leivone, S.K.; Undlien, E.; Nebdal, D.; Git, A.; Caldas, C.; Børresen-Dale, A.-L.; Kleivi, K. miR-342-5p As a Potential Regulator of HER2 Breast Cancer Cell Growth. *MicroRNA* 2019, 8, 155–165. [CrossRef] [PubMed]
54. Wu, X.; Somlo, G.; Yu, Y.; Palomares, M.R.; Li, A.X.; Zhou, W.; Chow, A.; Yen, Y.; Rossi, J.J.; Gao, H.; et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. *J. Transl. Med.* 2012, 10, 1–10. [CrossRef] [PubMed]
55. Zou, Q.; Yi, W.; Huang, J.; Fu, F.; Chen, G.; Zhong, D. MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells. *Exp. Ther. Med.* 2017, 14, 1198–1204. [CrossRef]
56. Ye, X.M.; Zhu, H.Y.; Bai, W.-D.; Wang, T.; Wang, L.; Chen, Y.; Yang, A.-G.; Jia, L.-T. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGFIR. *BMC Cancer* 2014, 14, 1–12. [CrossRef]
57. Tashkandi, H.; Shah, N.; Patel, Y.; Chen, H. Identification of new miRNA biomarkers associated with HER2-positive breast cancers. *Oncoscience* 2015, 2, 924–929. [CrossRef]
58. Han, B.; Huang, J.; Han, Y.; Hao, J.; Wu, X.; Song, H.; Chen, X.; Shen, Q.; Dong, X.; Pang, H.; et al. The microRNA miR-181c enhances chemosensitivities and reduces chemoresistance in breast cancer cells via down-regulating osteopontin. *Int. J. Biol. Macromol.* 2019, 125, 544–556. [CrossRef]
59. Zhao, L.; Wang, Y.; Jiang, L.; He, M.; Bai, X.; Yu, L.; Wei, M. MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). *J. Exp. Clin. Cancer Res.* 2016, 35, 1–14. [CrossRef]
60. Xi, C.; Wang, J.; Sun, H.; Zhang, X.; Kang, H. Loss of microRNA-30e induced by extracellular vesicles from cancer-associated fibroblasts promotes breast cancer progression by binding to CTHRC1. *Exp. Mol. Pathol.* 2021, 118, 104586. [CrossRef]
61. Shizhen, E.W.; Lin, R.-J. MicroRNA and HER2-overexpressing Cancer. *MicroRNA* 2013, 2, 137–147.
62. Fontana, A.; Barbano, R.; Dama, E.; Pasculli, B.; Rendina, M.; Morritti, M.G.; Melocchi, V.; Castelvetere, M.; Valori, V.M.; Ravaiolli, S.; et al. Combined analysis of miR-200 family and its significance for breast cancer. *Sci. Rep.* 2021, 11, 1–4. [CrossRef] [PubMed]
63. Liu, J.; Mao, Q.; Liu, Y.; Hao, X.; Zhang, S.; Zhang, J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. *Clin. J. Cancer Res.* 2013, 25, 46–54. [PubMed]
64. Zhang, H.; Li, B.; Zhao, H.; Chang, J. The expression and clinical significance of serum miR-205 for breast cancer and its role in detection of human cancers. *Int. J. Clin. Exp. Med.* 2015, 8, 3034–3043.
65. Ergün, S.; Ulaşlı, M.; Içici, Y.Z.; Içici, M.; Kirkbès, S.; Borazan, E.; Balık, A.; Yumrutaş, Ö.; Camci, C.; Cakmak, E.A.; et al. The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. *Mol. Biol. Rep.* 2015, 42, 497–505. [CrossRef]
66. Luo, Y.; Wang, X.; Niu, W.; Wang, H.; Wen, Q.; Fan, S.; Zhao, R.; Li, Z.; Xiong, W.; Peng, S.; et al. Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients. *Oncol. Lett.* 2017, 13, 867–874. [CrossRef]

67. Uhlaner, S.; Manusperke, H.; Zhang, J.D.; Horvat, E.A.; Schmidt, C.; Küllbeck, M.; Henjes, F.; Ward, A.; Tschulena, U.; Zweig, K.; et al. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. *Mol. Syst. Biol.* 2012, 8, 570. [CrossRef]

68. Fu, Y.; Xiong, J. MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3. *Croat. Med. J.* 2016, 57, 457–464. [CrossRef]

69. Nakanishi, H.; Taccioli, C.; Palatini, J.; Fernandez-Cymering, C.; Cui, R.; Kim, T.; Violinia, S.; Croce, C.M. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. *Oncogene* 2014, 33, 702–712. [CrossRef]

70. Xia, H.-F.; He, T.-Z.; Liu, C.-M.; Cui, Y.; Song, P.-P.; Jin, X.-H.; Ma, X. MiR-125b Expression Affects the Proliferation and Apoptosis of Human Glioma Cells by Targeting Bmf. *Cell Physiol. Biochem.* 2009, 23, 347–358. [CrossRef]

71. Le, M.T.N.; Teh, C.; Shyh-Chang, N.G.; Xie, H.; Zhou, B.; Korzh, V.; Lodish, H.F.; Lim, B. MicroRNA-125b is a novel negative regulator of p53. *Genes Dev.* 2009, 23, 862–876. [CrossRef]

72. Banzhaf-Strathmann, J.; Edbauer, D. Good guy or bad guy: The opposing roles of microRNA 125b in cancer. *Cancers* 2021, 7, 11, 4894. [CrossRef]

73. Tang, F.; Zhang, R.; He, Y.; Zou, M.; Guo, L.; Xi, T. MicroRNA-125b Induces Metastasis by Targeting STARBD13 in MCF-7 and MDA-MB-231 Breast Cancer Cells. *PloS ONE* 2012, 7, e35435. [CrossRef]

74. Scott, G.K.; Goga, A.; Bbaumik, D.; Berger, C.E.; Sullivan, C.S.; Benz, C.C. Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b. *J. Biol. Chem.* 2007, 282, 1479–1486. [CrossRef]

75. Wang, H.; Tan, G.; Dong, L.; Cheng, L.; Li, K.; Wang, Z.-B. Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer. *PloS ONE* 2012, 7, e34210. [CrossRef] [PubMed]

76. Zhou, M.; Liu, Z.; Zhao, Y.; Ding, Y.; Liu, H.; Yi, X.; Xiong, W.; Li, G.; Lu; J.; Fedstad, O.; et al. MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression. *J. Biol. Chem.* 2010, 285, 21496–21507. [CrossRef] [PubMed]

77. Wang, H.-J.; Guo, Y.-Q.; Tan, G.; Dong, L.; Cheng, L.; Li, K.-J.; Wang, Z.-Y.; Luo, H.-F. miR-125b Regulates Side Population in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy together with trastuzumab. *Breast Cancer Res. Pharmacol. Pharmacother.* 2019, 84, 1039–1049. [CrossRef]

78. Rodriguez-Martinez, A.; de Miguel-Pérez, D.; Ortega, F.G.; García-Puche, G.L.; Robles-Fernández, I.; Exposito, J.; Martorell-Marugan, J.; Carmona-Sáez, P.; Garrido-Navas, M.D.C.; Rolfos, C.; et al. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. *Breast Cancer Res. Treat.* 2019, 21, 1–13. [CrossRef]

79. Gong, C.; Yao, Y.; Wang, Y.; Liu, B.; Wu, W.; Chen, J.; Su, F.; Yao, H.; Song, E. Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer. *J. Biol. Chem.* 2011, 286, 19127–19137. [CrossRef]

80. De Mattos-Arruda, L.; Bottai, G.; Nuciforo, P.G.; Di Tommaso, L.; Giovannetti, E.; Veg, P.; Losurdo, A.; Pérez-Garcia, J.; Masci, G.; Corsi, F.; et al. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and HER2-positive breast cancer patients. *Oncotarget* 2015, 6, 37269. [CrossRef]

81. Jung, E.-J.; Santarpia, L.; Kim, J.; Esteva, F.J.; Moretti, E.; Buzdar, A.U.; Di Leo, A.; Le, X.-F.; Bast, R.C., Jr.; Park, S.-T.; et al. Plasma miR-210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. *Cancer* 2012, 118, 2603–2614. [CrossRef]

82. Zhang, Z.; Zhang, L.; Yu, G.; Sun, Z.; Wang, T.; Tian, X.; Duan, X.; Zhang, C. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer. *Cancer Chemother. Pharmacol.* 2020, 86, 761–772. [CrossRef]

83. Müller, V.; Gade, S.; Steinbach, B.; Loibl, S.; von Minckwitz, G.; Untch, M.; Schwealer, K.; Lübbe, K.; Schem, C.; Fasching, P.A.; et al. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2 positive breast cancer patients undergoing neoadjuvant therapy: A translational research project within the Geparquinto trial. *Breast Cancer Res. Treat.* 2014, 147, 61–68. [CrossRef]

84. Zhao, Q.; Liu, Y.; Wang, T.; Yang, Y.; Ni, H.; Liu, H.; Guo, Q.; Xi, T.; Zheng, L. MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. *Eur. J. Pharmacol.* 2020, 884, 173359. [CrossRef]

85. Bockhorn, J.; Dalton, R.; Nwachukwu, C.; Huang, S.; Prat, A.; Yee, K.; Chang, Y.F.; Huo, D.; Wen, Y.; Swanson, K.E.; et al. MicroRNA-30c inhibits human breast tumor chemoresistance by regulating TWF1 and IL-11. *Nat. Commun.* 2013, 4, 2393. [CrossRef]

86. Fang, Y.; Shen, H.; Cao, Y.; Li, H.; Qin, R.; Chen, Q.; Long, L.; Zhu, X.L.; Xie, C.J.; Xu, W.L. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ2 in breast cancer cells. *Braz. J. Med. Biol. Res.* 2014, 47, 60–69. [CrossRef] [PubMed]

87. Tormo, E.; Adam-Artigues, A.; Ballester, S.; Pineda, B.; Zazo, S.; González-Alonso, P.; Albalnelli, J.; Rovira, A.; Rojo, F.; Lluch, A.; et al. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. *Sci. Rep.* 2017, 7, 41309. [CrossRef] [PubMed]
89. Ichikawa, T.; Sato, F.; Terasawa, K.; Tsuchiya, S.; Toi, M.; Tsujimoto, G.; Shimizu, K. Trastuzumab Produces Therapeutic Actions by Upregulating mir-23a and miR-30b in Breast Cancer Cells. *PLoS ONE* 2012, 7, e31422. [CrossRef] [PubMed]

90. Li, Z.H.; Weng, X.; Xiong, Q.Y.; Tu, J.H.; Xiao, A.; Qiu, W.; Gong, Y.; Hu, E.W.; Huang, S.; Cao, Y.L. miR-34a expression in human breast cancer is associated with drug resistance. *Oncotarget* 2017, 8, 106270–106282. [CrossRef] [PubMed]

91. Rezaei, Z.; Sebazi, A.; Kordi-Tamandani, D.M.; Dastjerdi, K. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance. *DNA Cell Biol.* 2019, 38, 184–192. [CrossRef]

92. Noyan, S.; Gurdel, H.; Gur Dedegolu, B. Involvement of mir-770-5p in trastuzumab response in HER2 positive breast cancer cells. *PLoS ONE* 2019, 14, e0215894. [CrossRef] [PubMed]

93. Yang, F.; Fu, Z.; Yang, M.; Sun, C.; Li, Y.; Chu, J.; Zhang, Y.; Li, W.; Huang, X.; Li, J.; et al. Expression pattern of microRNAs related with response to trastuzumab in breast cancer. *J. Cell Physiol.* 2019, 234, 16102–16113. [CrossRef] [PubMed]

94. Li, Z.; Qin, Y.; Chen, P.; Luo, Q.; Shi, H.; Jiang, X. miR-135b-5p enhances the sensitivity of HER-2 positive breast cancer to trastuzumab via binding to cyclin D2. *Int. J. Mol. Med.* 2020, 46, 1514–1524. [CrossRef]

95. Li, Z.-H.; Xiong, Q.-Y.; Xu, L.; Duan, P.; Yang, Q.O.; Zhou, P.; Tu, J.H. miR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the insulin signaling pathway. *Oncotarget* 2017, 8, 32566–32575. [CrossRef] [PubMed]

96. Shen, H.; Li, L.; Yang, S.; Wang, D.; Zhong, S.; Zhao, J.; Tang, J. MicroRNA-29a contributes to drug-resistance of breast cancer cells to Adriamycin through PTEN/ATK/GSK3β signaling pathway. *Gene* 2016, 593, 89–90. [CrossRef]

97. Han, G.; Qiu, N.; Luo, K.; Liang, H.; Li, H. Downregulation of microRNA-141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4. *J. Cell Biochem.* 2019, 120, 11390–11400. [CrossRef] [PubMed]

98. Yu, J.; Li, Q.; Xu, Q.; Liu, L.; Jiang, B. MiR-148a inhibits angiogenesis by targeting ERBB3. *Cell. Res.* 2011, 21, 170–177. [CrossRef]

99. Ye, X.; Bai, W.; Zhu, H.; Zhang, X.; Chen, Y.; Wang, L.; Yang, A.; Zhao, J.; Jia, L. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancer cells by targeting PTEN. *BMB Rep.* 2014, 47, 268–273. [CrossRef]

100. Di Cosimo, S.; Appierto, V.; Pizzamiglio, S.; Silvestri, M.; Baselga, J.; Piccart, M.; Huober, J.; Izzquierdo, M.; de la Pena, L.; Hilbers, F.S.; et al. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. *Int. J. Mol. Sci.* 2020, 21, 1386. [CrossRef]

101. Cataldo, A.; Piovan, C.; Plantamura, I.; D’Ippolito, E.; Camelliti, S.; Casalini, P.; Giussani, M.; Dées, O.; Cairò, S.; Judde, J.-G.; et al. MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. *Oncotarget* 2018, 9, 27920–27928. [CrossRef]

102. Du, F.; Yuan, P.; Zhao, Z.T.; Yang, Z.; Wang, T.; Zhao, J.D.; Luo, Y.; Ma, F.; Wang, J.Y.; Fan, Y.; et al. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment. *Sci. Rep.* 2016, 6, 35509. [CrossRef]

103. Hsieh, T.-H.; Hsu, C.-Y.; Tsai, C.-F.; Long, C.-Y.; Chai, C.-Y.; Hou, M.-F.; Lee, J.N.; Wu, D.-C.; Wang, S.-C.; Tsai, E.-M. miR-125a-5p modulates the risk of disease recurrence in HER2-positive breast cancer. *PLoS ONE* 2015, 10, 0122365. [CrossRef] [PubMed]

104. Stankevicins, L.; Barat, A.; Dessen, P.; Vassetzky, Y.; de Moura Gallo, C.V. The microRNA-205-5p is correlated to metastatic potential of 21T series: A breast cancer progression model. *Oncotarget* 2016, 7, 32566–32575. [CrossRef] [PubMed]

105. Jiang, Q.; He, M.; Ma, M.-T.; Wu, H.-Z.; Yu, Z.-J.; Guan, S.; Jiang, L.-Y.; Wang, Y.; Zheng, D.-D.; Jin, F.; et al. MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1. *Oncol Rep.* 2016, 35, 1425–1432. [CrossRef]

106. Xue, J.; Chen, Z.; Gu, X.; Zhang, Y.; Zhang, W. MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13. *Tumour Biol.* 2016, 37, 1581–1590. [CrossRef]

107. Zhang, L.; Xing, M.; Wang, X.; Cao, W.; Wang, H. MiR-148a suppresses invasion and induces apoptosis of breast cancer cells by regulating USP4 and BIM expression. *Int. J. Clin. Exp. Pathol.* 2017, 10, 8361–8368. [PubMed]

108. Quan, Y.; Huang, X.; Quan, X. Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis. *Onco. Lett.* 2018, 16, 6638–6642. [CrossRef] [PubMed]

109. Fong, M.Y.; Zhou, W.; Liu, L.; Alontaga, A.Y.; Chandra, M.; Ashby, J.; Chow, A.; O’Connor, S.T.; Li, S.; Chin, A.R.; et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. *Nat. Cell Biol.* 2015, 17, 183–194. [CrossRef] [PubMed]

110. Miao, Y.; Wang, L.; Zhang, X.; Xing, R.G.; Zhou, W.W.; Liu, C.R.; Zhang, X.L.; Tian, L. miR-30a inhibits breast cancer progression through the Wnt/β-catenin pathway. *Int. J. Clin. Exp. Pathol.* 2019, 12, 241–250. [PubMed]

111. Zhang, J.; Yang, J.; Zhang, X.; Xu, J.; Sun, Y.; Zhang, P. MicroRNA-10b expression in breast cancer and its clinical association. *PLoS ONE* 2018, 13, e0192509. [CrossRef] [PubMed]

112. Liu, Y.; Zhao, J.; Zhang, P.Y.; Zhang, Y.; Sun, S.Y.; Yu, S.Y.; Xi, Q.S. MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. *Med. Sci. Monit.* 2012, 18, BR299–BR308. [CrossRef] [PubMed]

113. Huang, Q.; Gumireddy, K.; Schrier, M.; le Sage, C.; Nagel, R.; Nair, S.; Egan, D.A.; Li, A.; Huang, G.; Klein-Szanto, A.J.; et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. *Nat. Cell Biol.* 2008, 10, 202–210. [CrossRef] [PubMed]
114. Ding, Y.; Zhang, C.; Zhang, J.; Zhang, N.; Li, T.; Fang, J.; Zhang, Y.; Zuo, F.; Tao, Z.; Tang, S.; et al. miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-β1 expression. *Int. J. Oncol.* 2017, 50, 1701–1710. [CrossRef] [PubMed]

115. Zhao, H.; Kang, X.; Xia, X.; Wo, L.; Gu, X.; Hu, Y.; Xie, X.; Chang, H.; Lou, L.; Shen, X. miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. *Am. J. Transl. Res.* 2016, 8, 3106–3114.

116. Persson, H.; Kvist, A.; Rego, N.; Staaf, J.; Vallon-Christersson, J.; Luts, L.; Loman, N.; Jonsson, G.; Naya, H.; Hoglund, M.; et al. Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the ERBB2/Her2 Gene. *Cancer Res.* 2011, 71, 78–86. [CrossRef]

117. Lu, Q.; Guo, Z.; Qian, H. Role of microRNA-150-5p/SRCIN1 axis in the progression of breast cancer. *Exp. Ther. Med.* 2019, 17, 2221–2229. [CrossRef] [PubMed]

118. Li, F. Expression of miR-221 and miR-489 in breast cancer patients and their relationship with prognosis. *Oncol Lett.* 2020, 19, 1523–1529. [CrossRef] [PubMed]

119. Leivonen, S.K.; Sahlberg, K.K.; Mäkelä, R.; Due, E.U.; Kallioniemi, O.; Borresen-Dale, A.L.; Perälä, M. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. *Mol. Oncol.* 2014, 8, 93–104. [CrossRef] [PubMed]